Abstract:Background: The epigenetic factor protein arginine methyltransferase 5 (PRMT5) has been reported to play vital roles in a wide range of cellular processes, such as gene transcription, genomic organization, differentiation and cell cycle control. However, its role in pancreatic cancer remains unclear. Our study aimed to investigate the roles of PRMT5 in pancreatic cancer prognosis and progression and to explore the underlying molecular mechanism. Methods: Real-time PCR, immunohistochemistry and analysis of a dataset from The Cancer Genome Atlas (TCGA) were performed to study the expression of PRMT5 at the mRNA and protein levels in pancreatic cancer. Cell proliferation assays, including cell viability, colony formation ability and subcutaneous mouse model assays, were utilized to confirm the role of PRMT5 in cell proliferation and tumorigenesis. A Seahorse extracellular flux analyzer, a glucose uptake kit, a lactate level measurement kit and the measurement of 18F-FDG (fluorodeoxyglucose) uptake by PET/CT (positron emission tomography/computed tomography) imaging were used to verify the role of PRMT5 in aerobic glycolysis, which sustains cell proliferation. The regulatory effect of PRMT5 on cMyc, a master regulator of oncogenesis and aerobic glycolysis, was explored by quantitative PCR and protein stability measurements. Results: PRMT5 expression was significantly upregulated in pancreatic cancer tissues compared with that in adjacent normal tissues. Clinically, elevated expression of PRMT5 was positively correlated with worse overall survival in pancreatic cancer patients. Silencing PRMT5 expression inhibited the proliferation of pancreatic cancer cells both in vitro and in vivo. Moreover, PRMT5 regulated aerobic glycolysis in vitro in cell lines, in vivo in pancreatic cancer patients and in a xenograft mouse model used to measure 18F-FDG uptake. We found that mechanistically, PRMT5 posttranslationally regulated cMyc stability via F-box/WD repeat-containing protein 7 (FBW7), an E3 ubiquitin ligase that controls cMyc degradation. Moreover, PRMT5 epigenetically regulated the expression of FBW7 in pancreatic cancer cells. Conclusions: The present study demonstrated that PRMT5 epigenetically silenced the expression of the tumor suppressor FBW7, leading to increased cMyc levels and the subsequent enhancement of the proliferation of and aerobic glycolysis in pancreatic cancer cells. The PRMT5/FBW7/cMyc axis could be a potential therapeutic target for the treatment of pancreatic cancer.

Npm1 Activates Metabolic Changes by Inhibiting Fbp1 While Promoting the Tumorigenicity of Pancreatic Cancer Cells

YY1 Targets Tubulin Polymerisation-Promoting Protein to Inhibit Migration, Invasion and Angiogenesis in Pancreatic Cancer Via P38/mapk and PI3K/AKT Pathways

Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1

Overexpression of Pyruvate Dehydrogenase Phosphatase 1 Promotes the Progression of Pancreatic Adenocarcinoma by Regulating Energy-Related AMPK/mTOR Signaling

Inhibition of PTP1B Blocks Pancreatic Cancer Progression by Targeting the PKM2/AMPK/mTOC1 Pathway

NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation

Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells

NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response

NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma

PPM1G promotes autophagy and progression of pancreatic cancer via upregulating HMGB1

O-GlcNAcylation of FBP1 Promotes Pancreatic Cancer Progression by Facilitating Its Lys48-linked Polyubiquitination in Hypoxic Environments

A New Facet of NDRG1 in Pancreatic Ductal Adenocarcinoma: Suppression of Glycolytic Metabolism.

NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression

PPM1D Exerts Its Oncogenic Properties in Human Pancreatic Cancer Through Multiple Mechanisms

Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis

Cancer-associated Fibroblasts Employ NUFIP1-dependent Autophagy to Secrete Nucleosides and Support Pancreatic Tumor Growth.

PNMA1 Promotes Cell Growth in Human Pancreatic Ductal Adenocarcinoma.

The YY1-CPT1C signaling axis modulates the proliferation and metabolism of pancreatic tumor cells under hypoxia

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

Polycomb Complex Protein Bmi-1 Promotes Invasion and Metastasis of Pancreatic Cancer Stem Cells by Activating Pi3k/Akt Signaling, an Ex Vivo, in Vitro, and in Vivo Study